CXI Healthcare Technology Group Inkomsten in het verleden

Verleden criteriumcontroles 4/6

CXI Healthcare Technology Group is de winst gegroeid met een gemiddeld jaarlijks percentage van 70.7%, terwijl de Personal Products industrie de winst jaarlijks groeide met 12%. De inkomsten zijn gedaald met een gemiddelde snelheid van 7% per jaar. Het rendement op eigen vermogen van CXI Healthcare Technology Group is 6.1%, en het heeft een nettomarge van 42.3%.

Belangrijke informatie

70.7%

Groei van de winst

69.3%

Groei van de winst per aandeel

Personal Products Groei van de industrie	3.8%
Inkomstengroei	-7.0%
Rendement op eigen vermogen	6.1%
Nettomarge	42.3%
Laatste winstupdate	30 Jun 2024

Recente prestatie-updates uit het verleden

Recent updates

Insufficient Growth At CXI Healthcare Technology Group Limited (KOSDAQ:900120) Hampers Share Price

Sep 30

CXI Healthcare Technology Group (KOSDAQ:900120) Is Experiencing Growth In Returns On Capital

Aug 05

Lacklustre Performance Is Driving CXI Healthcare Technology Group Limited's (KOSDAQ:900120) Low P/S

May 30

How Much Did CKH Food & Health's(KOSDAQ:900120) Shareholders Earn From Share Price Movements Over The Last Five Years?

Dec 02

Opbrengsten en kosten

Hoe CXI Healthcare Technology Group geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

KOSDAQ:A900120 Opbrengsten, kosten en inkomsten (KRW Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Jun 24	69,420	29,349	5,600	4,939
31 Mar 24	67,194	21,013	3,401	5,231
31 Dec 23	68,673	17,446	4,305	5,611
30 Sep 23	69,715	12,117	6,971	7,873
30 Jun 23	71,617	7,528	10,442	9,750
31 Mar 23	79,065	1,294	13,352	12,812
31 Dec 22	87,718	3,198	13,294	13,550
30 Sep 22	98,052	9,532	12,327	9,969
30 Jun 22	101,376	5,981	12,437	9,317
31 Mar 22	103,312	6,182	13,586	5,963
31 Dec 21	105,354	4,302	14,554	3,998
30 Sep 21	108,284	2,762	15,390	5,424
30 Jun 21	104,593	5,098	12,846	3,818
31 Mar 21	81,035	-55,823	17,799	6,389
31 Dec 20	64,812	-70,201	23,388	9,016
30 Sep 20	63,264	-83,142	30,209	9,995
30 Jun 20	63,406	-98,437	39,211	10,858
31 Mar 20	82,358	-61,945	44,740	9,371
31 Dec 19	106,374	-64,559	50,190	8,496
30 Sep 19	117,046	-67,216	52,472	9,575
30 Jun 19	129,309	-70,621	54,781	11,801
31 Mar 19	147,921	-64,977	55,239	13,323
31 Dec 18	149,568	-66,308	57,169	13,316
30 Sep 18	148,347	-72,578	60,733	13,198
30 Jun 18	145,264	-73,933	62,473	12,874
31 Mar 18	120,456	-70,977	58,424	11,190
31 Dec 17	120,228	-49,884	51,365	9,909
30 Sep 17	125,336	-24,445	46,229	7,972
30 Jun 17	146,319	786	41,966	6,210
31 Mar 17	190,109	18,964	47,108	6,736
31 Dec 16	228,969	29,945	54,039	7,269
30 Sep 16	269,185	42,624	57,943	7,848
30 Jun 16	297,600	52,396	62,255	8,734
31 Mar 16	311,164	60,931	61,307	8,804
31 Dec 15	318,262	66,823	58,631	9,212
30 Sep 15	321,330	71,473	58,068	9,382
30 Jun 15	317,895	73,452	55,460	9,495
31 Mar 15	312,412	69,309	56,652	9,843
31 Dec 14	303,794	68,530	52,573	9,487
30 Sep 14	291,664	65,401	49,554	9,258
30 Jun 14	286,376	63,604	48,559	8,595
31 Mar 14	285,469	66,365	45,229	7,919
31 Dec 13	279,352	62,672	45,690	7,818

Kwaliteitswinsten: A900120 heeft een grote eenmalige winst van ₩10.3B wat gevolgen heeft voor de financiële resultaten van de laatste 12 maanden tot 30th June, 2024.

Groeiende winstmarge: De huidige netto winstmarges (42.3%) A900120 } zijn hoger dan vorig jaar (10.5%).

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: A900120 is de afgelopen 5 jaar winstgevend geworden en heeft de winst met 70.7% per jaar laten groeien.

Versnelling van de groei: De winstgroei van A900120 over het afgelopen jaar ( 289.9% ) overtreft het 5-jarig gemiddelde ( 70.7% per jaar).

Winst versus industrie: De winstgroei A900120 over het afgelopen jaar ( 289.9% ) overtrof de Personal Products -sector 75.4%.

Rendement op eigen vermogen

Hoge ROE: Het Rendement op eigen vermogen ( 6.1% ) van A900120 wordt als laag beschouwd.

CXI Healthcare Technology Group Inkomsten in het verleden

Verleden criteriumcontroles 4/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

First quarter 2024 earnings released: EPS: ₩34.00 (vs ₩16.00 in 1Q 2023)

Third quarter 2023 earnings released: ₩6.00 loss per share (vs ₩7.00 profit in 3Q 2022)

Second quarter 2023 earnings released: ₩41.00 loss per share (vs ₩2.00 loss in 2Q 2022)

First quarter 2023 earnings released: EPS: ₩16.00 (vs ₩11.00 loss in 1Q 2022)

Third quarter 2022 earnings released: EPS: ₩7.00 (vs ₩9.00 loss in 3Q 2021)

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Recent updates

New major risk - Shareholder dilution

CXI Healthcare Technology Group Limited announced that it has received KRW 999.999999 million in funding from Beauty Skin Corp.

CXI Healthcare Technology Group Limited, Annual General Meeting, Oct 24, 2024

CXI Healthcare Technology Group Limited, Annual General Meeting, Oct 24, 2024

Insufficient Growth At CXI Healthcare Technology Group Limited (KOSDAQ:900120) Hampers Share Price

CXI Healthcare Technology Group (KOSDAQ:900120) Is Experiencing Growth In Returns On Capital

Lacklustre Performance Is Driving CXI Healthcare Technology Group Limited's (KOSDAQ:900120) Low P/S

Investor sentiment improves as stock rises 28%

New major risk - Shareholder dilution

First quarter 2024 earnings released: EPS: ₩34.00 (vs ₩16.00 in 1Q 2023)

CKH Food & Health Limited announced that it has received KRW 7.432995165 billion in funding

New minor risk - Share price stability

Investor sentiment improves as stock rises 35%

Investor sentiment deteriorates as stock falls 16%

New major risk - Shareholder dilution

Third quarter 2023 earnings released: ₩6.00 loss per share (vs ₩7.00 profit in 3Q 2022)

Second quarter 2023 earnings released: ₩41.00 loss per share (vs ₩2.00 loss in 2Q 2022)

CKH Food & Health Limited has completed a Follow-on Equity Offering in the amount of KRW 999.99999 million.

First quarter 2023 earnings released: EPS: ₩16.00 (vs ₩11.00 loss in 1Q 2022)

No independent directors

Investor sentiment improved over the past week

CKH Food & Health Limited announced that it has received KRW 10.911791808 billion in funding from Rui Xing International Holdings Limited

CKH Food & Health Limited announced that it expects to receive KRW 10.911791808 billion in funding from Rui Xing International Holdings Limited, and other investors

Third quarter 2022 earnings released: EPS: ₩7.00 (vs ₩9.00 loss in 3Q 2021)

No independent directors

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Investor sentiment deteriorated over the past week

CKH Food & Health Limited has completed a Follow-on Equity Offering in the amount of KRW 999.99981 million.

Third quarter 2021 earnings released: ₩9.00 loss per share (vs ₩139 loss in 3Q 2020)

CKH Food & Health Limited announced that it has received KRW 2.270259148 billion in funding

CKH Food & Health Limited announced that it expects to receive KRW 2.270259148 billion in funding

CKH Food & Health Limited announced that it has received KRW 679.08 million in funding

CKH Food & Health Limited announced that it expects to receive KRW 679.08 million in funding

Second quarter 2021 earnings released: ₩17.00 loss per share (vs ₩133 loss in 2Q 2020)

New 90-day low: ₩405

First quarter 2021 earnings released: EPS ₩10.00

How Much Did CKH Food & Health's(KOSDAQ:900120) Shareholders Earn From Share Price Movements Over The Last Five Years?

New 90-day high: ₩354

New 90-day high: ₩295

New 90-day high: ₩274

New 90-day low - ₩212

Opbrengsten en kosten

Inkomsten en omzetgeschiedenis

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Rendement op eigen vermogen

Rendement op activa

Rendement op geïnvesteerd vermogen

Ontdek sterk presterende bedrijven uit het verleden